Very strong Q4 results beating expectations on all lines.

FY sales down but slightly better than expected

A new drug looks promising in the weight loss sector

Burberry Outperforms Expectations in Q3 Amid Strategic Turnaround Efforts

Strong beat in Q4 and massive beat in dividend.

FY24 Earnings Outlook Confirmed, Cautious on FY25 leading to a consensus downgrade.